Connecting lysosomes and mitochondria - a novel role for lipid metabolism in cancer cell death.
Apoptosis
Cardiolipin
Fission
Lipid metabolism
Lysosome
Mitochondria
V-ATPase
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
29 07 2019
29 07 2019
Historique:
received:
16
05
2019
accepted:
15
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
17
6
2020
Statut:
epublish
Résumé
The understanding of lysosomes has been expanded in recent research way beyond their view as cellular trash can. Lysosomes are pivotal in regulating metabolism, endocytosis and autophagy and are implicated in cancer. Recently it was discovered that the lysosomal V-ATPase, which is known to induce apoptosis, interferes with lipid metabolism in cancer, yet the interplay between these organelles is poorly understood. LC-MS/MS analysis was performed to investigate lipid distribution in cells. Cell survival and signaling pathways were analyzed by means of cell biological methods (qPCR, Western Blot, flow cytometry, CellTiter-Blue). Mitochondrial structure was analyzed by confocal imaging and electron microscopy, their function was determined by flow cytometry and seahorse measurements. Our data reveal that interfering with lysosomal function changes composition and subcellular localization of triacylglycerids accompanied by an upregulation of PGC1α and PPARα expression, master regulators of energy and lipid metabolism. Furthermore, cardiolipin content is reduced driving mitochondria into fission, accompanied by a loss of membrane potential and reduction in oxidative capacity, which leads to a deregulation in cellular ROS and induction of mitochondria-driven apoptosis. Additionally, cells undergo a metabolic shift to glutamine dependency, correlated with the fission phenotype and sensitivity to lysosomal inhibition, most prominent in Ras mutated cells. This study sheds mechanistic light on a largely uninvestigated triangle between lysosomes, lipid metabolism and mitochondrial function. Insight into this organelle crosstalk increases our understanding of mitochondria-driven cell death. Our findings furthermore provide a first hint on a connection of Ras pathway mutations and sensitivity towards lysosomal inhibitors.
Sections du résumé
BACKGROUND
The understanding of lysosomes has been expanded in recent research way beyond their view as cellular trash can. Lysosomes are pivotal in regulating metabolism, endocytosis and autophagy and are implicated in cancer. Recently it was discovered that the lysosomal V-ATPase, which is known to induce apoptosis, interferes with lipid metabolism in cancer, yet the interplay between these organelles is poorly understood.
METHODS
LC-MS/MS analysis was performed to investigate lipid distribution in cells. Cell survival and signaling pathways were analyzed by means of cell biological methods (qPCR, Western Blot, flow cytometry, CellTiter-Blue). Mitochondrial structure was analyzed by confocal imaging and electron microscopy, their function was determined by flow cytometry and seahorse measurements.
RESULTS
Our data reveal that interfering with lysosomal function changes composition and subcellular localization of triacylglycerids accompanied by an upregulation of PGC1α and PPARα expression, master regulators of energy and lipid metabolism. Furthermore, cardiolipin content is reduced driving mitochondria into fission, accompanied by a loss of membrane potential and reduction in oxidative capacity, which leads to a deregulation in cellular ROS and induction of mitochondria-driven apoptosis. Additionally, cells undergo a metabolic shift to glutamine dependency, correlated with the fission phenotype and sensitivity to lysosomal inhibition, most prominent in Ras mutated cells.
CONCLUSION
This study sheds mechanistic light on a largely uninvestigated triangle between lysosomes, lipid metabolism and mitochondrial function. Insight into this organelle crosstalk increases our understanding of mitochondria-driven cell death. Our findings furthermore provide a first hint on a connection of Ras pathway mutations and sensitivity towards lysosomal inhibitors.
Identifiants
pubmed: 31358011
doi: 10.1186/s12964-019-0399-2
pii: 10.1186/s12964-019-0399-2
pmc: PMC6664539
doi:
Substances chimiques
Muramidase
EC 3.2.1.17
Vacuolar Proton-Translocating ATPases
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Références
FASEB J. 2015 Jun;29(6):2439-49
pubmed: 25678624
Cancer Res. 2015 Jul 15;75(14):2863-74
pubmed: 26018087
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Biochim Biophys Acta. 2008 Sep;1777(9):1092-7
pubmed: 18519024
Mol Cancer Ther. 2014 Apr;13(4):926-37
pubmed: 24482380
J Pharmacol Exp Ther. 2011 Nov;339(2):487-98
pubmed: 21856859
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8788-93
pubmed: 20421486
J Bioenerg Biomembr. 2007 Aug;39(4):321-9
pubmed: 17917797
Mol Cell. 2015 Feb 5;57(3):521-36
pubmed: 25658204
J Control Release. 2017 May 28;254:107-118
pubmed: 28342982
Mol Cell. 2016 Mar 3;61(5):648-653
pubmed: 26942669
Nat Rev Mol Cell Biol. 2013 May;14(5):283-96
pubmed: 23609508
J Cell Biochem. 2010 Mar 1;109(4):634-42
pubmed: 20039309
Arch Pathol Lab Med. 2015 Oct;139(10):1224-33
pubmed: 26414466
Sci Rep. 2017 Jan 17;7:40620
pubmed: 28094777
Nat Rev Cancer. 2003 Jan;3(1):11-22
pubmed: 12509763
Biochim Biophys Acta. 2013 Jan;1833(1):205-12
pubmed: 22406072
Oncogene. 2010 Sep 9;29(36):4989-5005
pubmed: 20639898
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
J Lipid Res. 2018 Feb;59(2):298-311
pubmed: 29208696
Nat Cell Biol. 2013 Jun;15(6):647-58
pubmed: 23604321
Ann N Y Acad Sci. 2016 May;1371(1):45-54
pubmed: 26599426
Biochim Biophys Acta. 2009 Oct;1788(10):2022-31
pubmed: 19450542
Sci Signal. 2010 Dec 07;3(151):pl3
pubmed: 21139138
EMBO J. 2012 Mar 7;31(5):1095-108
pubmed: 22343943
Hepatology. 2008 Oct;48(4):1312-27
pubmed: 18821591
Science. 2011 Nov 4;334(6056):678-83
pubmed: 22053050
Gastroenterology. 2019 Mar;156(4):1173-1189.e5
pubmed: 30452922
J Biol Chem. 2003 Aug 22;278(34):31861-70
pubmed: 12805375
Oncotarget. 2017 Feb 7;8(6):9476-9487
pubmed: 28036299
Annu Rev Genet. 2009;43:95-118
pubmed: 19659442
Int J Cancer. 2014 May 15;134(10):2478-88
pubmed: 24166050
J Gastroenterol Hepatol. 2009 May;24(5):703-6
pubmed: 19646010
J Biol Chem. 2013 Jan 11;288(2):1385-96
pubmed: 23168408
Annu Rev Cell Dev Biol. 2016 Oct 6;32:255-278
pubmed: 27298091
EMBO J. 2016 Mar 1;35(5):479-95
pubmed: 26813791
World J Biol Chem. 2012 Aug 26;3(8):167-74
pubmed: 22937213
Am J Physiol Cell Physiol. 2007 Jan;292(1):C33-44
pubmed: 16899548
Mol Med Rep. 2019 Apr;19(4):2767-2773
pubmed: 30720142
Dev Cell. 2014 Jul 14;30(1):86-94
pubmed: 25026035
Nat Rev Mol Cell Biol. 2009 Sep;10(9):623-35
pubmed: 19672277
Cell Res. 2012 Feb;22(2):399-412
pubmed: 21876558
Cell Signal. 2002 Aug;14(8):717-22
pubmed: 12020772
Am J Cancer Res. 2018 May 01;8(5):778-791
pubmed: 29888102
FEBS J. 2012 Aug;279(15):2610-23
pubmed: 22621751
Dev Cell. 2014 Jul 14;30(1):95-102
pubmed: 25026036
Cancer Res. 2012 Nov 15;72(22):5976-87
pubmed: 22986742
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
Mol Cancer Res. 2011 Nov;9(11):1551-61
pubmed: 21954435
Front Cell Dev Biol. 2017 Dec 07;5:106
pubmed: 29270406